Our findings suggest that novel therapies for muscular injury, particularly through Antcin K, warrant further clinical investigations to validate its efficacy and safety in humans, with an emphasis on understanding the molecular mechanisms involved and exploring IL-10 targeting as a potential innovative approach to controlling sarcopenia and enhancing muscle mass and function in the aging population. This evidence concerns the gene IL10 and sarcopenia.